# Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects

> **NCT00660387** · PHASE3 · COMPLETED · sponsor: **AbbVie (prior sponsor, Abbott)** · enrollment: 35 (actual)

## Conditions studied

- Advanced Parkinson's Disease

## Interventions

- **DRUG:** Levodopa carbidopa intestinal gel (LCIG)
- **DRUG:** Placebo Gel
- **DRUG:** Levodopa-carbidopa (LC) oral encapsulated immediate release (IR) tablets
- **DRUG:** Placebo (PBO) oral capsules
- **DEVICE:** CADD-Legacy® 1400 ambulatory infusion pump
- **DEVICE:** PEG tube
- **DEVICE:** J-tube

## Key facts

- **NCT ID:** NCT00660387
- **Lead sponsor:** AbbVie (prior sponsor, Abbott)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2011-10
- **Final completion:** 2011-10
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2015-01-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00660387

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00660387, "Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00660387. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*